Patoloxía Molecular das Doenzas Raras
PatMol-DR
Kaiser Permanente San Francisco Medical Center
San Francisco, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von Kaiser Permanente San Francisco Medical Center (1)
2024
-
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 10, pp. 725-734